US judge sets hearing for Biogen vs Elan dispute over Tysabri
This article was originally published in Scrip
Executive Summary
A federal judge has agreed to give Biogen Idec expedited discovery relating to documents concerning an ongoing dispute with Elan. Elan is fighting a claim from Biogen Idec that its recent $1.5 billion deal with Johnson & Johnson placed it in material breach of the commercialisation pact for the multiple sclerosis drug Tysabri (natalizumab). A hearing, originally set for the end of August, has been moved to September 10th.